FDA committee to review compounding eligibility for seven peptides in July

The Food and Drug Administration's Pharmacy Compounding Advisory Committee will meet on July 23 and July 24, 2026, to evaluate seven popular peptides for 503A compounding eligibility. The committee will review BPC-157, KPV, TB-500, and MOTS-c on the first day of the meeting, followed by Emideltide (DSIP), Semax, and Epitalon on the second day. Ahead of this scheduled review, the FDA moved BPC-157 out of its more restrictive Category 2 classification, a step that cleared the path for this formal committee evaluation.

For aesthetics and wellness clinics utilizing these compounds in regenerative or anti-aging protocols, the outcome of this July 2026 meeting will define exactly which peptides can legally be prepared by compounding pharmacies under Section 503A. A negative ruling would effectively halt the legal compounding of these specific agents, while a positive recommendation would secure their place in clinical compounding. Clinic owners should review their current inventory of these seven peptides, particularly BPC-157 and TB-500, and prepare for potential prescribing shifts depending on the committee's final determination.

Source: Momentum Wellness / Aesthetics Journal, https://www.peptidesstuart.com/blog/fda-peptide-review-2026-what-it-means-for-your-care